Thromboprophylaxis
Gallus AS et al.
Small subcutaneous doses of heparin in prevention of venous thrombosis.
Fraisse F et al.
Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD. The Association of Non-University Affiliated Intensive Care Specialist Physicians of France.
Reversing anticoagulants
Eerenberg ES et al.
Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects.
Circulation. 2011 Oct 4;124(14):1573-9. doi: 10.1161/CIRCULATIONAHA.111.029017. Epub 2011 Sep 6.
Transfusion
For haemorrhage in trauma see Trauma Key Papers
TRICC – Hébert PC et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. New England Journal of Medicine. 1999;340(6):409–17. TRICC CVS disease – Hébert PC et al. Is a low transfusion threshold safe in critically ill patients with cardiovascular diseases? Crit Care Med. 2001 Feb;29(2):227–34. TRICC trauma – McIntyre L et al. Is a restrictive transfusion strategy safe for resuscitated and critically ill trauma patients? J Trauma. 2004 Sep;57(3):563–568; discussion 568. TRICC head injury – McIntyre LA et al. Effect of a liberal versus restrictive transfusion strategy on mortality in patients with moderate to severe head injury. Neurocrit Care. 2006;5(1):4–9.TRISS – Holst LB et al.
Lower versus Higher Hemoglobin Threshold for Transfusion in Septic Shock.
Lacroix J et al.
Age of transfused blood in critically ill adults.
Platelets
Stanworth SJ et al.
Prophylactic platelet transfusion for haemorrhage after chemotherapy and stem cell transplantation.
Cochrane Database Syst Rev. 2004;(4):CD004269.
Slichter SJ et al.
Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med. 2010 Feb 18;362(7):600–13. Stanworth SJ et al. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. N Engl J Med. 2013 May 9;368(19):1771–80.Transfusion-associated lung injury
Marik PE, Corwin HL.
Acute lung injury following blood transfusion: Expanding the definition.
Critical Care Medicine. 2008 Nov;36(11):3080–4.
Erythropoietin
Shermock KM et al.
Erythropoietic agents for anemia of critical illness.
Am J Health Syst Pharm. 2008 Mar 15;65(6):540–6.
Mesgarpour B et al.
‘Safety of off-Label Erythropoiesis Stimulating Agents in Critically Ill Patients: A Meta-Analysis’.
Antifibrinolytics
Mangano DT et al.
Multicenter Study of Perioperative Ischemia Research Group, Ischemia Research and Education Foundation. The risk associated with aprotinin in cardiac surgery.
N Engl J Med. 2006 Jan 26;354(4):353–65.
CRASH-2 Shakur H et al.
‘Effects of Tranexamic Acid on Death, Vascular Occlusive Events, and Blood Transfusion in Trauma Patients with Significant Haemorrhage (CRASH-2): A Randomised, Placebo-Controlled Trial’.
Lancet 376, no. 9734 (3 July 2010): 23–32. doi:10.1016/S0140-6736(10)60835-5.
MATTERs – Morrison JJ et al.
Military Application of Tranexamic Acid in Trauma Emergency Resuscitation (MATTERs)
Study. Arch Surg. 2012 Feb;147(2):113–9.
Wardrop D et al.
Antifibrinolytics (lysine analogues) for the prevention of bleeding in patients with haematological disorders.
Cochrane Database Syst Rev. 2013;7:CD009733.